This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $140.24, moving -1.39% from the previous trading session.
Veeva's (VEEV) Vault EDC to Boost Vita Global's Data Management
by Zacks Equity Research
Veeva's (VEEV) Vault EDC is likely to improve Vita Global's clinical data management processes.
McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.
Patterson Companies (PDCO) Q4 Earnings Miss, Sales Rise Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fourth-quarter fiscal 2024 results reflect a year-over-year improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales improve.
Venus Concept's (VERO) Latest Supply Deal to Aid its Business
by Zacks Equity Research
Venus Concept (VERO) announces an exclusive strategic supply arrangement with Skin Laundry Holdings, Inc.
BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold
by Zacks Equity Research
BrainsWay's (BWAY) latest exclusive multi-year distribution agreement is likely to provide improved patient care in Canada.
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Philips' (PHG) Diagnosis & Treatment Segment Drives Growth
by Zacks Equity Research
Philips (PHG) boosts Diagnosis & Treatment on the back of Precision Diagnosis and Image-Guided Therapy businesses and an expanding partner base.
Merit Medical (MMSI) Recalls Syringes Made by Jiangsu Shenli
by Zacks Equity Research
Merit Medical (MMSI) recalls certain products containing syringes made by a Chinese manufacturer, Jiangsu Shenli.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Care in Mexico
by Zacks Equity Research
GE HealthCare's (GEHC) latest agreement is likely to standardize care protocols and improve the quality of CT, MR and ultrasound examinations.
Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?
by Zacks Equity Research
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy
by Zacks Equity Research
Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
by Zacks Equity Research
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.
3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
DaVita HealthCare (DVA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
DaVita HealthCare (DVA) reachead $142.16 at the closing of the latest trading day, reflecting a -0.37% change compared to its last close.
Patterson Companies' (PDCO) Launch to Boost Insurance Workflow
by Zacks Equity Research
Patterson Companies' (PDCO) latest offering is likely to offer customers additional options for their electronic insurance processing and patient billing statement workflow.
HealthEquity (HQY) Gains 25.3% YTD: What's Driving the Rally?
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
by Zacks Equity Research
Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.
Philips (PHG) Aids Image-Guided Treatment With New Stent System
by Zacks Equity Research
Philips (PHG) boosts its Image-Guided Therapy portfolio with the Duo Venous Stent System, strengthening its Diagnosis & Treatment segment.
3 PEG-Based Value Picks to Boost Your Portfolio Returns
by Urmimala Biswas
Invest in shares of Eldorado Gold (EGO), Sasol (SSL) and DaVita (DVA) that hold huge upside potential.
DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?
by Zacks Equity Research
DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.